Summary & Overview
CPT 0474U: GeneticsNow® Comprehensive Germline Pan–Cancer Panel
CPT code 0474U designates a Proprietary Laboratory Analyses (PLA) test specific to GoPath Diagnostics Inc.: the GeneticsNow® Comprehensive Germline Panel. This hereditary pan–cancer assay analyzes 88 genes by next-generation sequencing (NGS) with Sanger confirmation and targeted deletion/duplication interrogation, reporting positive or negative germline findings for each gene. The code matters nationally as precision germline testing increasingly informs cancer risk assessment, family counseling, and downstream clinical management.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise policy and coverage context, typical clinical use cases, and operational considerations for laboratories and clinicians billing under this PLA code. The publication outlines service characteristics (NGS + Sanger on blood or saliva, laboratory setting), typical sites of service, and common modifiers used in billing practice. It highlights what stakeholders should expect in terms of coding specificity for a manufacturer‑ or lab‑unique test and clarifies that 0474U must be reported only for the GeneticsNow® Comprehensive Germline Panel.
The report also covers benchmarking and payer coverage themes, practical coding guidance for claim submission, and the clinical implications of reporting binary (positive/negative) germline results across the 88‑gene panel. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 0474U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the GeneticsNow® Comprehensive Germline Panel from GoPath Diagnostics Inc. The test is a hereditary pan–cancer genomic sequence analysis that interrogates a panel of 88 genes associated with inherited cancer syndromes, including sarcomas, endocrine tumors, neuroendocrine tumors, and cutaneous melanoma. It reports results as positive or negative for each gene, indicating the presence or absence of germline variants that may predispose individuals to cancer.
Service type: Laboratory — genetic testing (next-generation sequencing and Sanger confirmation)
Typical site of service: Clinical laboratory processing using blood or saliva specimens
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient referred to genetic counseling for evaluation of hereditary cancer risk undergoes the GeneticsNow® Comprehensive Germline Panel (0474U). The typical patient is an adult with a personal history of cancer (for example, early-onset breast cancer, multiple primary tumors, sarcoma, endocrine tumor, neuroendocrine tumor, or cutaneous melanoma) or with a strong family history of cancers suggesting an inherited predisposition. The clinical workflow: a genetics provider or ordering clinician obtains informed consent and collects a blood or saliva sample, which is sent to GoPath Diagnostics for the GeneticsNow® 88-gene panel. The laboratory performs next-generation sequencing with confirmatory Sanger sequencing and targeted duplication/deletion analysis, and reports each gene as positive or negative for pathogenic germline variants. Results are returned to the ordering clinician and genetic counselor for review, risk assessment, and communication to the patient, with implications for surveillance, cascade testing of relatives, and potential targeted therapies or preventive interventions where applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — global or default billing | Use when no special circumstances or additional modifier applies to the lab service. |